Wall Street analysts expect that GW Pharmaceuticals PLC (NASDAQ:GWPH) will report earnings of ($1.73) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for GW Pharmaceuticals PLC’s earnings, with the highest EPS estimate coming in at ($1.28) and the lowest estimate coming in at ($2.18). GW Pharmaceuticals PLC posted earnings of ($0.73) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 137%. The firm is expected to announce its next earnings report on Tuesday, August 8th.

On average, analysts expect that GW Pharmaceuticals PLC will report full-year earnings of ($6.28) per share for the current year, with EPS estimates ranging from ($7.48) to ($5.08). For the next financial year, analysts forecast that the firm will post earnings of ($4.81) per share, with EPS estimates ranging from ($5.09) to ($4.52). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover GW Pharmaceuticals PLC.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.50) by $0.20. GW Pharmaceuticals PLC had a negative return on equity of 22.81% and a negative net margin of 1,021.38%. The company had revenue of $2.04 million for the quarter, compared to the consensus estimate of $2.07 million. During the same period in the previous year, the business posted ($0.06) EPS. The business’s revenue for the quarter was down 23.0% on a year-over-year basis.

GWPH has been the topic of a number of recent analyst reports. Maxim Group set a $135.00 price target on shares of GW Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Thursday, June 8th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $185.00 price target on shares of GW Pharmaceuticals PLC in a research report on Wednesday, February 22nd. Cantor Fitzgerald restated a “buy” rating and issued a $208.00 price target on shares of GW Pharmaceuticals PLC in a research report on Tuesday, May 9th. TheStreet upgraded shares of GW Pharmaceuticals PLC from a “d+” rating to a “c-” rating in a research report on Tuesday, March 14th. Finally, BidaskClub upgraded shares of GW Pharmaceuticals PLC from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 14th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. GW Pharmaceuticals PLC has a consensus rating of “Buy” and a consensus price target of $144.50.

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) traded up 2.942% during trading on Monday, hitting $100.605. 91,201 shares of the stock traded hands. GW Pharmaceuticals PLC has a one year low of $79.62 and a one year high of $137.88. The firm has a 50 day moving average price of $104.54 and a 200-day moving average price of $115.98. The company’s market cap is $2.55 billion.

ILLEGAL ACTIVITY NOTICE: “Zacks: Analysts Expect GW Pharmaceuticals PLC (GWPH) to Announce -$1.73 Earnings Per Share” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/06/19/zacks-analysts-expect-gw-pharmaceuticals-plc-gwph-to-announce-1-73-earnings-per-share.html.

Several institutional investors have recently made changes to their positions in the company. Jennison Associates LLC raised its position in shares of GW Pharmaceuticals PLC by 212.1% in the first quarter. Jennison Associates LLC now owns 466,345 shares of the biopharmaceutical company’s stock worth $56,400,000 after buying an additional 316,926 shares during the last quarter. Franklin Resources Inc. raised its position in shares of GW Pharmaceuticals PLC by 3.4% in the fourth quarter. Franklin Resources Inc. now owns 438,470 shares of the biopharmaceutical company’s stock worth $48,999,000 after buying an additional 14,300 shares during the last quarter. Morgan Stanley raised its position in shares of GW Pharmaceuticals PLC by 17.6% in the first quarter. Morgan Stanley now owns 301,472 shares of the biopharmaceutical company’s stock worth $36,461,000 after buying an additional 45,111 shares during the last quarter. Alliancebernstein L.P. raised its position in shares of GW Pharmaceuticals PLC by 4.6% in the first quarter. Alliancebernstein L.P. now owns 286,475 shares of the biopharmaceutical company’s stock worth $34,646,000 after buying an additional 12,519 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of GW Pharmaceuticals PLC by 10.4% in the first quarter. Victory Capital Management Inc. now owns 283,025 shares of the biopharmaceutical company’s stock worth $34,229,000 after buying an additional 26,638 shares during the last quarter. Institutional investors own 75.65% of the company’s stock.

About GW Pharmaceuticals PLC

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.